Biogen Inc. or Novavax, Inc.: Who Invests More in Innovation?

Biogen Inc. vs. Novavax, Inc.: A Decade of Innovation Investment

In the ever-evolving landscape of biotechnology, investment in research and development (R&D) is a key driver of innovation. Over the past decade, Biogen Inc. and Novavax, Inc. have demonstrated contrasting approaches to R&D spending. From 2014 to 2023, Biogen consistently outpaced Novavax, investing nearly four times more on average. Notably, in 2020, Biogen's R&D expenses peaked, reaching a staggering 4 billion dollars, while Novavax saw its highest investment in 2021, with a significant surge to 2.5 billion dollars, likely driven by the global demand for COVID-19 vaccines. Despite Novavax's impressive growth in recent years, Biogen's sustained commitment to innovation underscores its leadership in the biotech sector. As the industry continues to advance, these investments will play a crucial role in shaping the future of healthcare.